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AbstrAct
Objectives There have been few clinical trials (CTs) 
on antibiotics that inform neonatal and paediatric drug 
labelling. The rate of unlicensed and off-label prescribing 
in paediatrics remains high. It is unclear whether the 
current neonatal and paediatric antibiotic research pipeline 
is adequate to inform optimal drug dosing. Using the  
ClinicalTrials. gov registry, this review aims to establish the 
current global status of antibiotic CTs in children up to 18 
years of age. 
Methods Studies were identified using key word searches 
of the  ClinicalTrials. gov registry and were manually filtered 
using prespecified inclusion/exclusion criteria.
results 76 registered open CTs of antibiotics in children 
were identified globally; 23 (30%) were recruiting 
newborns (only 8 (11%) included preterm neonates), 
52 (68%) infants and toddlers, 58 (76%) children and 
54 (71%) adolescents. The majority of registered trials 
were late phase (10 (15%) phase 3 and 23 (35%) phase 
4/pharmacovigilance). Two-thirds were sponsored by 
non-profit organisations, compared with pharmaceutical 
companies (50 (66%) vs 26 (34%), respectively). A greater 
proportion of non-profit funded trials were efficacy-based 
strategic trials (n=34, 68%), in comparison with industry-
led trials, which were most often focused on safety or 
pharmacokinetic data (n=17, 65%). Only 2 of the 37 
antibiotics listed on the May 2016 Pew Charitable Trusts 
antibiotic development pipeline, currently being studied in 
adults, appear to be currently recruiting in open paediatric 
CTs.
conclusions This review highlights that very few 
paediatric antibiotic CTs are being conducted globally, 
especially in neonates. There is a striking disparity noted 
between antibiotic drug development programmes in 
adults and children.
IntrOductIOn
Widespread unlicensed and off-label 
prescribing in paediatrics persists—as high 
as 11.4% and 46.5%, respectively—yet the 
paucity of clinical research involving chil-
dren that is conducted to inform optimal 
drug dosing, licensing and labelling remains 
a problem.1 For certain medicines, drug effi-
cacy can be extrapolated from adult data 
provided that the pathology and drug expo-
sure are the same or sufficiently similar in 
children as in adults.2 3 Although differences 
in drug pharmacokinetics (PK) in neonates 
and children can lead to adverse reactions 
that are not seen in adult populations, these 
are very rare.4 Suboptimal antibiotic dosing, 
including underdosing and overdosing, can 
lead to toxicity and treatment failure and may 
drive antimicrobial resistance by encouraging 
selection pressures on drug-resistant strains 
of bacteria.5
Since antibiotics are the most commonly 
prescribed medicines in children, it is 
important to maximise our understanding of 
their PK profiles to help determine optimal 
drug dosing and ultimately to improve 
outcomes.6 In the last decade, several initia-
tives have been established to encourage 
paediatric medicines research, bridging 
the gap between adult and paediatric drug 
development plans. Such initiatives include 
the Paediatric Regulation (Paediatric Inves-
tigation Plans (PIPs), introduced by the 
European Medicines Agency (EMA),7 and 
Pediatric Study Plans, by the US Food and 
Drug Administration (FDA)).8 Despite this, 
there have been few advances in antibiotic 
development for this population.9
The global status of clinical research on 
antibiotics in paediatrics is unknown. Using 
registered records of clinical trials (CTs) 
on  ClinicalTrials. gov, this review aims (1) 
to summarise the current global status of 
registered antibiotic research in children 
and neonates and (2) to stimulate discus-
sion and collaboration among the relevant 
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Figure 1 Flow chart. Clinical trial selection process.
stakeholders on the neglect of antibiotic research in 
children.
MethOds
data sources
The  ClinicalTrials. gov registry (last accessed 8 November 
2016) is an international platform for the registration of 
CTs. It is a web-based registry, developed in 2000 by the 
National Institutes of Health and the FDA, to which trials 
from 50 states and 163 countries around the world are 
registered. Information provided for each trial is updated 
periodically by the trial’s sponsoring organisation. The 
database has a specific child filter, which uses a key word 
paradigm to select all registered trials recruiting patients/
participants up to 18 years of age.
study selection
Our records were identified using suitable key word 
searches, in which the final search terms were (antimicro-
bial* OR antibiotic* OR anti-infective agent*) AND Child 
AND Open Studies. All identified trials were filtered 
manually using inclusion and exclusion criteria. Interven-
tional and observational trials on antimicrobials recruiting 
children up to 18 years of age were considered eligible 
for inclusion. No specific temporal filter was applied 
since only open or ongoing clinical trials were of interest. 
The following records, which were not investigating one 
or more antibiotics, were excluded: trials of antiseptics, 
antifungals, antiprotozoals, antivirals and probiotics or 
prebiotics. The following records, which were investi-
gating an antibiotic, were excluded: trials involving tuber-
culosis, malaria, cystic fibrosis, HIV, febrile neutropenic 
patients, topical or inhalational treatments and prophy-
lactic antibiotics or records investigating alternative use 
for antibiotics (eg, as an anti-inflammatory agent).
The searches were conducted by GT. All eligible records 
were identified via manual filtering by GT, CIB, LF and 
MS, and any disagreements regarding inclusion and 
exclusion of records were resolved through discussion.
data extraction
The following information was collected from the 
included records: unique  ClinicalTrials. gov identifier 
(NCT number), recruitment status, study design, trial 
phase, study sponsor, age group and sex eligibility, clinical 
indication, geographic region of recruitment, antibiotic 
being investigated and endpoint classification. Outcomes 
were categorised as safety, efficacy or PK. Economic setting 
(based on geographic region of recruitment) was classi-
fied using The World Bank classification to differentiate 
between low-income countries (LICs), lower income and 
middle-income countries (LMICs), upper middle-income 
Countries (UMICs) and high-income countries (HICs).10
The specific class of antibiotic studied in each trial was 
identified and classified using the WHO Anatomical, 
Therapeutic, and Chemical classification and Defined 
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Table 1 Characteristics of clinical trials
Characteristic Category
Number of 
studies, n (%)
Age group Preterm neonates 1 (1)*
Neonates (total) 23 (30)
Infants and toddlers 52 (68)
Children 58 (76)
Adolescents 54 (71)
Recruitment status Recruiting 63 (83)
Not yet recruiting 13 (17)
Study design Interventional 66 (87)
Observational 10 (13)
Trial phase† Phase 1 10 (15)
Phases 1–2 1 (2)
Phase 2 9 (14)
Phases 2–3 3 (5)
Phase 3 10 (15)
Phase 4 23 (39)
Not specified 10 (15)
Sponsor Industry 26 (34)
Non-profit 50 (66)
Geographic region Africa 8 (11)
Asia 16 (21)
Europe 22 (29)
Latin America 6 (8)
North America 34 (45)
Oceania 5 (7)
Antibiotic class J01A Tetracycline 4 (5)
J01C Beta-lactam, 
penicillin
25 (33)
J01D Other beta-lactam 22 (29)
J01E Sulfonamides and 
trimethoprim
7 (9)
J01F Macrolide, 
lincosamide, 
streptogramin
14 (18)
J01G Aminoglycoside 2 (3)
J01M Quinolone 8 (11)
J01X Other antibiotic 
classes‡
21 (28)
J01 Not specified 2 (3)
Totals for age group, geographic region and antibiotic class do 
not add up to total number of clinical trials (76) as some trials 
contributed to more than one subgroup.
*Seven further trials mentioned inclusion of preterm babies in 
the inclusion criteria.
†Trial phase % based on percentage of interventional trials.
‡J01X includes glycopeptides, polymyxins, imidazole and 
nitrofuran derivatives.
Table 2 Clinical trial endpoint classification of identified 
clinical trials stratified by trial sponsor
Endpoint 
classification Industry Non-profit Total (%)
Efficacy 9 34 43 (57)
Safety 10 2 12 (16)
PK 7 14 21 (28)
Endpoint classification determined by planned primary outcomes.
PK, pharmacokinetics.
Daily Dose (ATC/DDD) index.11 To investigate whether 
novel antibiotics are being studied in paediatric popu-
lations, the antibiotics currently studied in children 
were compared with the Pew Charitable Trusts Antibiotics 
Currently in Clinical Development pipeline, which identifies 
novel antibiotics currently under development for the US 
market.12
results
Our search identified 1056 records. Six hundred and 
three records were excluded on title because they were 
studies not involving an antimicrobial. Four hundred and 
fifty-three records were investigating one or more anti-
microbials and recruiting children below 18 years of age. 
Among the 195 trials investigating antibiotics, 76 fulfilled 
our inclusion and exclusion criteria and were included in 
the final analysis. Reasons for exclusion are summarised 
in figure 1. Details of included studies can be found in 
online supplementary file 1.
All 76 CTs identified were open as of 8 November 2016, 
and 63 (83%) of these were recognised as recruiting 
participants on this date (table 1). All trials stated recruit-
ment of both male and female participants.
Age group
Twenty-three of the 76 trials (30%) were recruiting 
newborns (0–28 days). One of these 23 trials focused 
solely on recruiting preterm newborns (a further 7 CTs 
mentioned inclusion of preterm newborns in inclusion 
criteria). Of the remaining records, 52 (68%) were 
recruiting infants and toddlers (28 days–23 months), 58 
(76%) children (2–11 years) and 54 (71%) adolescents 
(11–18 years). Twenty-nine (38%) trials did not focus 
solely on the recruitment of children or neonates, with 
age ranges also spanning across adult populations.
study type
Interventional trials were most frequently identified 
(n=66, 87%) with only 10 (13%) observational trials 
noted. Of the interventional trials, the majority were in 
the later stages of development; 10 (13%) in phase 1, 1 
(2%) between phases 1 and 2, 9 (14%) in phase 2, 3 (5%) 
between phase 2 and phase 3, 10 (15%) in phase 3 and 
23 (35%) in phase 4. In 10 (15%) cases, a trial phase was 
not specified.
sponsor and endpoint classification
Fifty trials (66%) were sponsored by non-profit organisa-
tions (being university, hospital or government funded), 
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Table 3 Clinical indication of identified clinical trials stratified by age group being recruited
Indication Total (%)
Age group
Preterm neonates Neonates* Infants and toddlers Children Adolescents
Unspecified bacterial infection 18 (24) – 11 15 15 14
Lower respiratory tract infection 12 (16) 1 3 12 13 5
Sepsis 11 (14) – 6 9 9 11
Upper respiratory tract 8 (11) – 1 5 9 7
Intra-abdominal infection 8 (11) – 3 5 5 7
Urinary tract infection 7 (9) – 2 6 7 6
Skin and soft tissue infection 6 (8) – 3 4 4 8
CNS infection 3 (4) – 1 4 4 4
Bone and joint Infection 1 (1) – – 1 1 1
1 30 61 67 63
Age group totals do not add up to total number of clinical trials (76) as some trials contributed to more than one age group.
*Total number of preterm and term neonates.
and 26 trials were sponsored by industry (34%). The 
endpoint classification of the majority of trials (n=43, 
57%) was reported as efficacy (table 2). A greater propor-
tion (n=34, 68%) of non-profit studies measured the 
efficacy of the drugs as the primary endpoint, with less 
emphasis on collection of PK or safety data (n=16, 32%). 
In comparison, pharmaceutical-led trials focused on early 
PK and safety studies over the drug’s efficacy (n=17, 65% 
vs n=9, 35%, respectively).
Geographic region
The most frequently recruiting geographic region was 
North America (n=34, 45%). Twenty-two (29%) trials 
recruiting in Europe and 16 (21%) in Asia were iden-
tified, 6 (8%) in Latin America, 8 (11%) in Africa and 
5 (7%) in Oceania. Most trials were recruiting in HICs 
(n=54, 71%), with fewer trials recruiting in LICs (n=4, 
5%), LMICs (n=4, 5%), UMICs (n=11, 14%) or a combi-
nation of UMICs and HICs (n=3, 4%).
Indication
The most common treatment indications investigated 
were lower respiratory tract infection (n=12, 16%) and 
sepsis (n=11, 14%), followed by upper respiratory tract 
infection (n=8, 11%), intra-abdominal infection (IAI) 
(n=8, 11%), urinary tract infection (UTI) (n=7, 9%), 
complicated skin and soft tissue infection (cSSTI) (n=6, 
8%), central nervous system (CNS) infection (n=3, 4%) 
and bone and joint infection (n=1, 1%) (table 3).
Antibiotic class
The majority of antibiotics being investigated were 
beta-lactams (n=47, 62%), followed by other antibiotic 
classes (J01X, including vancomycin, telavancin and 
dalbavancin) (n=21, 28%). Macrolides or lincosamides 
(J01F) were the next most commonly studied antibiotic 
classes (n=14, 18%). Very few trials were investigating 
of tetracyclines (J01A) (n=4, 5%), sulphonamides and 
trimethoprim (J01E) (n=7, 9%), aminoglycosides (J01G) 
(n=2, 3%) or quinolones (J01M) (n=8, 11%). Two CTs 
(3%) did not specify the class of antibiotic being investi-
gated. Sixteen (21%) trials were investigating more than 
one antibiotic; these trials counted towards more than 
one J01 category. The breakdown of J01 categories, as per 
WHO ATC/DDD classification,11 is described in table 1.
Antibiotic pipeline
Of the 37 antibiotics listed in the May 2016 edition of the 
Pew Charitable Trusts Antibiotic Pipeline (last accessed 
10 June 2016),12 as noted by the EMA Opinions and Deci-
sions on Pediatric Investigation Plans, five had an agreed 
PIP: imipenem/cilastatin+relebactam, cadazolid, carba-
vance (meropenem+vaborbactam), eravacycline and soli-
thromycin.8 As of 8 November 2016, our search found 
that only 2 of these 37 antibiotics listed (carbavance 
and solithromycin) were being investigated in 1 and 2 
ongoing CTs in paediatric patients, respectively (table 4). 
A PIP was agreed for carbavance in 2015 for treatment of 
Gram-negative infections, and for solithromycin in 2016 
for the treatment of gonococcal infection, and later for 
treatment of anthrax, tularaemia and bacterial pneu-
monia. PIPs were agreed in 2015 for treatment of UTI 
and complicated IAI with eravacycline, and in 2016 for 
treatment of Clostridium difficile infection with cadazolid 
and of Gram-negative bacterial infection with imipenem/
cilastin+relebactam.13 Despite this, we could not identify 
any registered trials of these antibiotics in our search.
dIscussIOn
Our search identified 76 clinical trials investigating 
one or more antibiotics recruiting children between 
0 and 18 years of age. This is low in comparison with 
the number of ongoing trials in adults, despite children 
representing around a quarter of the global popula-
tion.14 15 A review of completed CTs in the USA between 
2000 and 2010 identified a total of 4078 adult trials 
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compared with just 294 that had recruited children.16 
In our study, the lack of trials recruiting neonates is 
striking. Just 23 of the 76 trials identified were recruiting 
neonates and remarkably just 8 CTs globally were 
recruiting preterm neonates. There are broadly two 
types of paediatric trials conducted globally: (1) phar-
maceutical-led phase 1/2 PK and safety trials (n=17) 
being conducted in the HIC setting, and (2) investiga-
tor-led, often pragmatic, late phase efficacy trials in the 
LMIC setting (n=34). Amongst these a greater propor-
tion of ongoing trials are sponsored by non-profit 
organisations over industry (66% compared with 
34%). As of April 2016, there were 17 antibiotic PIPs 
agreed by the EMA,8 covering a range of indications, 
most commonly cSSTI, complicated IAI (cIAI) and 
complicated UTI (cUTI).13 In contrast, treatments for 
respiratory and systemic infections, the most common 
clinical indications for antibiotics in paediatrics, are not 
currently being evaluated.14 Thirty-seven antibiotics are 
currently being developed in adults, yet to our knowl-
edge, just two of these are being studied in children. 
Some classes of antibiotics that may be of higher risk 
for children (tetracyclines and fluoroquinolones) may 
not be pursued as aggressively for paediatric approvals 
due to well-recognised issues of toxicity, particularly 
when safer alternatives are widely available. Given that 
Gram-negative sepsis is a growing problem in neonates, 
with a significant increase in the proportion of multi-
resistant Gram-negative pathogens,15 the substantial lag 
time between the submission date (for PIP or waiver) 
and declared completion date of PK studies in adults 
is a real concern, although there is value in generating 
substantial safety data in adults prior to exposing chil-
dren and newborns to potentially toxic new agents.
In 2013, a similar review of European paediatric clin-
ical trials identified 31 trials of antibiotics approved for 
adults by the EMA in 2000 that were recruiting chil-
dren in Europe (compared with the 22 trials we found 
recruiting in Europe). They included both published 
and ongoing trials, which likely accounts for the higher 
number of trials reported. They similarly found a 
very small proportion of neonatal trials (2 of 31), as 
well as a greater proportion of efficacy-based trials.9 
A review of interventional trials registered with  Clini-
calTrials. gov between 2007 and 2010 found that only 
17% had recruited children below 18 years of age.17 A 
similar review of antimicrobial CTs conducted in the 
USA between 2000 and 2012 reported that just 5% 
had recruited only children compared with 74% that 
recruited only adults, and that, as we have found, the 
trials were sponsored primarily by non-profit organisa-
tions (60% vs 30% by industry).14 In our search of global 
trials, 39% of registered CTs reported collection of PK 
data in comparison with a 2009 paediatric PK research 
review that reported 24% of registered CTs would be 
collecting PK data.18
The search strategy used has some limitations. Since 
the search was limited to clinical trials registered with 
 7Thompson G, et al. BMJ Open 2017;7:e016293. doi:10.1136/bmjopen-2017-016293
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ClinicalTrials. gov, it is possible other open or ongoing 
trials registered with alternative platforms (eg, the WHO 
International Clinical Trials Registry Platform) will have 
been missed. Together with  ClinicalTrials. gov, these could 
help to establish the entirety of current clinical research in 
this field. We did, however, search EudraCT and found no 
further studies beyond those captured on  ClinicalTrials. 
gov. Our search was also limited to open CTs, thereby 
missing active but not yet recruiting trials and those 
that had already closed to recruitment. The information 
recorded for each trial registered with  ClinicalTrials. gov 
is updated by the trial investigators, and therefore relies 
on them to periodically update the registry. Occasion-
ally, information such as recruitment status might not be 
updated in real time.
Concerns around the growing threat of antimicrobial 
resistance have prompted several new initiatives. In 2016, 
the EMA published a draft concept paper to propose the 
development of an addendum to the guideline on the 
evaluation of new antibacterial products for treatment 
of bacterial infections in children.19 At the same time, 
the Clinical Trials Transformation Initiative is currently 
focused on the identification of key barriers in the 
conduct of paediatric antibacterial CTs, which hamper 
their successful implementation into clinical practice.20 
Recent evidence states that, overall, antibiotic CTs make 
up less than 1% of all registered paediatric CTs and that 
trial completion is slow, with an average time to comple-
tion of around 2 years.21 There are specific areas where 
the design and conduct of paediatric antibiotic CTs can 
be harmonised and simplified, such as the standardisa-
tion of the inclusion and exclusion criteria for specific 
clinical infection syndromes, and improved bridging of 
safety and efficacy data from other age groups; these 
advances could improve trial conduct and efficiency in 
children.22
cOnclusIOns
This review highlights that very few paediatric antibi-
otic CTs are being conducted globally, particularly in 
neonates. There is a marked disparity between antibiotic 
drug development programmes in adults and children. 
Many issues contribute to the difficulties in conducting 
paediatric antibiotic clinical trials. The lack of regulatory 
guidance, vulnerability of this population, issues with 
informed consent and assent and lack of research-ex-
perienced hospital personnel all present challenges in 
study design, delivery and recruitment. Delays in the 
initial start-up of CTs in paediatrics due to paediatric-spe-
cific protocol issues and complicated ethical approval 
continue to discourage both academic and pharmaceu-
tical interest. The limited data presented here suggest 
that the dismal state of paediatric antibiotic research 
continues. Earlier collaboration between global academic 
research networks and pharmaceutical companies is now 
vital to accelerate progress.
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